12:00 AM
 | 
Sep 17, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

SecreFlo regulatory update

Repligen withdrew an MAA for SecreFlo to improve detection of pancreatic duct abnormalities in combination with MRI in patients with known or suspected pancreatitis. The company said the move is part...

Read the full 131 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >